These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 1861941)

  • 61. Dosage of zidovudine for treatment of AIDS.
    J Am Board Fam Pract; 1990; 3(2):131. PubMed ID: 2333762
    [No Abstract]   [Full Text] [Related]  

  • 62. Fifth International Conference on the acquired immunodeficiency syndrome.
    Tindall B; Cotton R; Swanson C; Perdices M; Bodsworth N; Imrie A; Cooper DA
    Med J Aust; 1990 Feb; 152(4):204-11, 214. PubMed ID: 1967816
    [No Abstract]   [Full Text] [Related]  

  • 63. Health beliefs and discontinuation of zidovudine therapy.
    Geletko SM; Ballard CR; Mathews WC
    Am J Health Syst Pharm; 1995 Mar; 52(5):505-7. PubMed ID: 7606554
    [No Abstract]   [Full Text] [Related]  

  • 64. [Medical admission and treatment].
    Rosenthal E
    Soins; 1992 Jan; (556):12-5. PubMed ID: 1609319
    [No Abstract]   [Full Text] [Related]  

  • 65. Emerging concepts in the treatment of HIV infection in children.
    Pizzo PA
    JAMA; 1989 Oct; 262(14):1989-92. PubMed ID: 2778935
    [No Abstract]   [Full Text] [Related]  

  • 66. AIDS therapy and the detection of adverse drug effects in dental practice.
    Arrowsmith JB
    J Am Dent Assoc; 1989 Nov; Suppl():46S-48S. PubMed ID: 2592694
    [No Abstract]   [Full Text] [Related]  

  • 67. Intermittent high-dose zidovudine.
    Price LA; Hill BT; Gelmon KA
    Lancet; 1989 Sep; 2(8665):734. PubMed ID: 2570973
    [No Abstract]   [Full Text] [Related]  

  • 68. Using experiential training to enhance health professionals' awareness of patient compliance issues.
    Morse EV; Simon PM; Balson PM
    Acad Med; 1993 Sep; 68(9):693-7. PubMed ID: 8397635
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection.
    Connor E; Morrison S; Lane J; Oleske J; Sonke RL; Connor J
    Antimicrob Agents Chemother; 1993 Mar; 37(3):532-9. PubMed ID: 8460922
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Treatment of symptomatic children infected with human immunodeficiency virus.
    Shearer WT
    J Infect Dis; 1990 Nov; 162(5):1209-10. PubMed ID: 2230248
    [No Abstract]   [Full Text] [Related]  

  • 71. Prophylactic zidovudine for a child after human immunodeficiency virus needlestick exposure.
    Wilfert CM
    Pediatr Infect Dis J; 1990 Aug; 9(8):600-1. PubMed ID: 2235183
    [No Abstract]   [Full Text] [Related]  

  • 72. Zidovudine in post-exposure prophylaxis of health-care workers.
    Puro V; Ippolito G
    Lancet; 1990 May; 335(8698):1166-7. PubMed ID: 1971903
    [No Abstract]   [Full Text] [Related]  

  • 73. Cardiomyopathy related to acquired immunodeficiency syndrome in children.
    Steinherz LJ
    J Pediatr; 1996 May; 128(5 Pt 1):721. PubMed ID: 8627455
    [No Abstract]   [Full Text] [Related]  

  • 74. Lethal neurotoxicity associated to azidothymidine therapy.
    Saracchini S; Vaccher E; Covezzi E; Tortorici G; Carbone A; Tirelli U
    J Neurol Neurosurg Psychiatry; 1989 Apr; 52(4):544-5. PubMed ID: 2500498
    [No Abstract]   [Full Text] [Related]  

  • 75. The Trivacan study.
    Nüesch R
    Lancet; 2006 Sep; 368(9539):915-6; author reply 916. PubMed ID: 16962873
    [No Abstract]   [Full Text] [Related]  

  • 76. Measures of effect based on the sufficient causes model. 1. Risks and rates of disease associated with a single causative agent.
    Allard R; Boivin JF
    Epidemiology; 1993 Jan; 4(1):37-42. PubMed ID: 8420579
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Vertical human immunodeficiency virus-1 infection: involvement of the central nervous system and treatment.
    Exhenry C; Nadal D
    Eur J Pediatr; 1996 Oct; 155(10):839-50. PubMed ID: 8891552
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS.
    Van Rompay KK; Otsyula MG; Marthas ML; Miller CJ; McChesney MB; Pedersen NC
    Antimicrob Agents Chemother; 1995 Jan; 39(1):125-31. PubMed ID: 7695293
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Low-dose zidovudine in children with an human immunodeficiency virus type 1 infection acquired in the perinatal period.
    Blanche S; Duliege AM; Navarette MS; Tardieu M; Debré M; Rouzioux C; Seldrup J; Kouzan S; Griscelli C
    Pediatrics; 1991 Aug; 88(2):364-70. PubMed ID: 1861941
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group.
    McKinney RE; Maha MA; Connor EM; Feinberg J; Scott GB; Wulfsohn M; McIntosh K; Borkowsky W; Modlin JF; Weintrub P
    N Engl J Med; 1991 Apr; 324(15):1018-25. PubMed ID: 1672443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.